| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | RHD |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen. [1] [2]
It is currently at Phase III trials for Rh disease.
The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.
Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.
Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Pritumumab (PTB) is a human monoclonal antibody targeted against glioma. It works by binding to the ecto-domain of vimentin on the surface of cancer cells. developed by Nascent Biotech.
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma.
Clenoliximab (INN) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.
Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.
Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.
Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma. It binds to IGHE.
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.
Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.
Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.
Fletikumab (NNC0109-0012) (INN) is a monoclonal antibody designed for the treatment of rheumatoid arthritis that targets IL-20.
Vanucizumab is an experimental humanized monoclonal antibody designed for the treatment of cancer.
Depatuxizumab mafodotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
Rosmantuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Flotetuzumab is a bispecific antibody designed for the treatment of acute myeloid leukemia.
Spartalizumab is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |